Share on StockTwits
 

GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reaffirmed by investment analysts at Bank of America Corp. in a note issued to investors on Tuesday, Analyst Ratings.Net reports. They currently have a GBX 2,050 ($32.05) target price on the stock. Bank of America Corp.’s target price indicates a potential upside of 28.25% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Monday. They now have a GBX 2,000 ($31.27) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Monday. They now have a GBX 1,960 ($30.64) price target on the stock. Finally, analysts at UBS AG reiterated a “neutral” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Friday. They now have a GBX 1,745 ($27.28) price target on the stock.

Five analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 1,644.93 ($25.72).

GlaxoSmithKline (LON:GSK) traded down 2.53% during mid-day trading on Tuesday, hitting GBX 1598.50. The stock had a trading volume of 16,036,005 shares. GlaxoSmithKline has a one year low of GBX 1194.5601 and a one year high of GBX 1816.00. The stock has a 50-day moving average of GBX 1669. and a 200-day moving average of GBX 1635.. The company’s market cap is £77.447 billion.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.